KSR1 and hepatocellular carcinoma: The significance of the Moon et al. study lies in its pioneering demonstration that KSR1 inhibition represents a viable therapeutic strategy for HCC, thereby broadening the spectrum of actionable nodes within the RAS/MAPK signaling network.